Brainsway Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Brainsway Ltd., a foreign private issuer, on November 4, 2025. The report covers the month of November 2025 and serves to disclose a specific corporate development rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes and Developments
The primary material event disclosed is the award of a grant from the National Institutes of Health (NIH). The grant is designated for a leading U.S. research team to investigate the use of Brainsway's Accelerated Deep Transcranial Magnetic Stimulation (TMS) technology for the treatment of Alcohol Use Disorder.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the context of the research grant. No unusual items were reported.
Key Facts for Investor Verification
- Verify the specific dollar amount and duration of the NIH grant awarded for the Alcohol Use Disorder study.
- Confirm the identity of the U.S. research team leading the investigation.
- Review the study protocol and timeline for the Accelerated Deep TMS trial.
- Check for any subsequent press releases detailing the grant's impact on the company's R&D pipeline.